Video
Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer
Author(s):
Video Player is loading.
Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.
Related Videos
Study findings highlight gender gaps in oncology authorship and citation
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
Related Content
